Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	3 Months Ended		39 Months Ended
	Jul. 31, 2013	Jul. 31, 2012	Jul. 31, 2013
Cash flows from operating activities:
Net loss	$ (1,294,854)	$ (4,750,232)	$ (18,737,157)
Adjustment to reconcile net loss to net cash used in operating activities
Equity issued for acquisition of One E-Commerce Corporation			534,365
Equity issued for payment of accounts payable - related party			10,000
Stock based compensation		128,106	6,163,412
Derivative liabilities	24,283	380,435	921,332
Amortization of intangible assets	7,601	7,601	98,813
Accrued stock compensation expenses	239,000	3,007,200	1,438,067
Changes in operating assets and liabilities:
Advances to related party			(2,405)
Prepaid Expenses		(67,500)	(50,000)
Accounts payable	988,134	81,240	3,141,897
Accounts payable - related party		(14,228)	(20,000)
Net cash used in operating activities	(35,836)	(1,227,378)	(6,501,676)
Cash flows from investing activities:
Net cash provided by investing activities
Cash flows from financing activities:
Proceeds from issuance of common stock		1,891,182	4,597,416
Subscribers shares-not issued			1,504,865
Proceeds from notes payable-related party	32,362		432,862
Payments on notes payable-related party			(33,352)
Net cash provided by financing activities	32,362	1,891,182	6,501,791
Net (decrease) increase in cash	(3,474)	663,804	115
Cash, beginning of period	3,589	1,908,532
Cash, end of period	115	2,572,336	115
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING INFORMATION:
Shares issued for settlement of accrued expenses		1,135,365	1,135,365
Shares issued for settlement of derivative liabilities		753,288	838,461
Shares issued for issuance of subscribed shares - not issued		1,097,265	1,408,265
Shares issued for acquisition of Diakine Therapeutics, Inc.			2,829,823
Net liabilities assumed in acquisition of Diakine Therapeutics, Inc.			101,284
Deferred income tax liability and goodwill associated with the acquisition of Diakine Therapeutics, Inc.			547,000
Common stock issued in exchange for convertible notes			357,000
Common stock issued in exchange for intangible asset			200,000
Common stock issued in exchange for accounts payable - related party			$ 10,000